-
admin
Posts
EpiVax Drives Immunogenicity Innovation in 2024: Year in Review
PROVIDENCE, R.I., Dec. 7, 2024 /PRNewswire/ — EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked...
SECU Kicks Off Statewide Beautification Initiative with Keep North Carolina Beautiful
High Point project helps keep water and the environment safe for people and wildlife HIGH POINT, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) — State Employees’...
Bring Home 2025’s Cottage Chic Trend With The Tile Shop’s Newest Collaboration With Laura Ashley
The Laura Ashley tile collection is available exclusively at The Tile Shop’s 142 U.S. showrooms and tileshop.com MINNEAPOLIS, Dec. 06, 2024 (GLOBE NEWSWIRE) — As...
1 BTC Lottery: FUJIYAMA TAP Launches Globally on Telegram – A New Gaming Experience Celebrating Mt. Fuji
HONOLULU, Dec. 06, 2024 (GLOBE NEWSWIRE) — FUJIYAMA TAP, a casual tap-based game for Telegram users, will officially launch worldwide on December 9, 2024. Centered...
IGPDecaux wins Rome’s iconic bus shelter contract in Italy
IGPDecaux wins Rome’s iconic bus shelter contract in Italy Paris, December 6th, 2024 – JCDecaux SE (Euronext Paris: DEC), the number one outdoor advertising company...
Fungicides Market to Reach USD 37.8 Billion by 2032 Driven by Increasing Demand for Food Security and Crop Protection Solutions | Report Published by SNS Insider
The rise in demand for Fungicides-based beauty and healthcare products continues to accelerate due to advancements in scientific research and increasing consumer awareness about Fungicides’s...
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Zevra Therapeutics Announces Organizational Changes
CELEBRATION, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs...
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and...
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight...
